3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Centene reported third quarter 2026 results on October 27, 2026, with a GAAP diluted loss of $(0.14) per share and adjusted diluted EPS of $0.58, compared with $0.50 a year earlier. The company raised its full-year 2026 adjusted diluted EPS guidance by $0.40 to greater than $5.20 and its GAAP diluted EPS guidance to greater than $3.46. For shareholders, the higher guidance and improved quarterly profit compared with 2025 point to a faster earnings recovery than the company had previously expected.
Q3 2026 GAAP diluted loss per share was $(0.14), compared with a $(13.50) loss in Q3 2025, which included a $6.7 billion goodwill impairment.
Q3 2026 adjusted diluted EPS was $0.58, up from $0.50 in Q3 2025.
Full-year 2026 adjusted diluted EPS guidance rose to greater than $5.20; GAAP diluted EPS guidance is greater than $3.46.
Total debt was reduced by $1.1 billion since June 30, 2026, including full redemption of the 2027 Senior Notes in October 2026.
Nautilus Biotechnology reported third quarter 2026 results for the period ended September 30, 2026, with revenue of $0.2 million, mainly grant revenue, compared with no revenue a year earlier. Net loss widened to $15.6 million from $13.6 million as operating expenses rose 10% to $16.9 million, and cash, cash equivalents and investments stood at $114.3 million at quarter end.
Q3 2026 revenue was $0.2 million, primarily grant revenue tied to a Michael J. Fox Foundation grant, versus no revenue in Q3 2025.
Operating expenses rose $1.5 million, or 10%, to $16.9 million, driven by higher laboratory, professional services and salary costs.
Net loss was $15.6 million, or $0.12 per share, compared with $13.6 million, or $0.11 per share, a year earlier.
Cash, cash equivalents and investments were $114.3 million as of September 30, 2026; the company said it expects up to $6 million from the ARPA-H-funded SEEDS consortium.
Community Bancorp. reported third-quarter 2026 net income of $5.1 million, or $0.91 per share, up from $4.7 million, or $0.84 per share, a year earlier. Net income for the first nine months was $14.1 million, or $2.53 per share, up 14.72%, alongside higher net interest income. For shareholders, per-share earnings rose, while the securities portfolio carried a $13.4 million reduction to equity from unrealized losses.
Q3 2026 net income was $5.1 million, up 7.24% from $4.7 million; earnings per share were $0.91 versus $0.84.
Nine-month 2026 net income was $14.1 million, or $2.53 per share, up 14.72% from $12.3 million.
Q3 net interest income rose 10.89% to $11.7 million, while non-interest income fell 8.98% to $1.9 million.
Quarterly dividend of $0.26 per share is payable November 1, 2026, to shareholders of record as of October 15, 2026.
Polaris reported third quarter 2026 sales of $2,043 million, up 11% from a year earlier, and diluted EPS of $0.66 versus a loss of $0.28 a year earlier. The company raised its full-year 2026 adjusted EPS guidance to $3.50 to $3.60 from $3.00 to $3.10, and raised adjusted sales guidance to $7.55 billion to $7.60 billion from $7.30 billion to $7.50 billion. Shareholders benefit from stronger sales and profit, though about $1.09 of the adjusted EPS guidance comes from tariff refunds recorded in the second and third quarters.
Q3 2026 sales were $2,043 million, up 11%; North America sales rose 14% to $1,815 million.
Q3 diluted EPS was $0.66 (net income attributable to Polaris of $38.4 million), compared with a $0.28 loss per share a year earlier; adjusted diluted EPS was $1.08 versus $0.41.
Q3 results include $10 million of tariff refunds, which added $0.13 to adjusted EPS.
Full-year 2026 adjusted EPS guidance is $3.50 to $3.60, up from $3.00 to $3.10; the company said about $1.09 of this is attributed to tariff refunds.
Perpetua Resources amended warrants covering 1,607,802 common shares, extending each expiry by up to six months. Its subsidiary also entered a cost-share Tungsten OTIA with the U.S. Army to evaluate tungsten concentrate production at the Stibnite Mining District, with a total estimated cost of up to about $85 million and a cost-share of up to $45 million. The filing gives shareholders a clearer view of potential dilution timing and a new federal-funded exploration program, though the filing notes later phases depend on future approvals and results.
Warrants for 1,607,802 common shares at $31.46 and $38.93 had original expiries of October 28, December 1 and December 23, 2026; each is extended by up to six months.
Tungsten OTIA total estimated cost is up to about $85 million, with cost-share of up to $45 million over a period ending October 19, 2029.
Subsidiary Perpetua Resources Idaho will match the U.S. Army's $40 million contribution; the initial 18-month phase is expected to cost about $18 million, shared equally.
On October 20, 2026, Bold Eagle Acquisition Corp. shareholders approved extending the date to complete an initial business combination from October 25, 2026 to June 25, 2027. Holders of 15,397,025 Class A shares redeemed for about $10.70 per share, leaving about $111,311,833 in the trust account, but non-redemption agreements with several investors are expected to keep more funds in the trust than would otherwise remain.
Extension Amendment Proposal approved: 20,448,699 for, 497,774 against, 0 abstentions.
15,397,025 Class A shares redeemed at about $10.70 per share; about $111,311,833 left in the trust account.
Investors reversed their redemptions in exchange for monthly cash deposits of $134,507 into escrow, funded by the sponsor, until the earliest of a business combination closing, liquidation, or June 25, 2027.
Sponsor converted 5,159,999 Class B shares to Class A shares on October 23, 2026; 15,562,974 Class A shares were outstanding as of October 26, 2026.
Dollar General disclosed that the FTC and various states filed a lawsuit against it on October 26, 2026, in federal court in Tennessee, alleging violations of the FTC Act, the Gramm-Leach-Bliley Act and state consumer protection laws. The FTC had also demanded significant monetary relief, and the company says it intends to defend the case but cannot assure a successful outcome, which could have a material adverse effect on its consolidated financial statements.
FTC and states filed suit October 26, 2026, in the U.S. District Court for the Middle District of Tennessee
Plaintiffs seek injunctive relief, monetary judgment and civil penalties; the filing does not state an amount
Draft complaint and draft settlement order were received September 23, 2026, after a Civil Investigative Demand dated January 30, 2026
Company says it will vigorously defend the matter and that defense could involve significant costs
FF EAI Robotics Ecosystem said it completed its acquisition of the robotics business of Faraday Future Intelligent Electric on October 23, 2026, paying with common and non-voting convertible preferred shares issued to a Faraday Future subsidiary. It also gave first-time full-year 2026 guidance of about 2,000 robots on a standalone basis, but the filing reports no revenue, profit, or EPS results, and the share issuance may dilute existing holders.
Acquisition closed October 23, 2026; consideration was common and non-voting convertible preferred shares issued to Smart Technology Holdings Ltd., a Faraday Future subsidiary
Standalone 2026 guidance of about 2,000 robots with positive unit gross margins; the company will consolidate the acquired business only from October 23, 2026
October sales and shipments expected to exceed 300 robots; cumulative sales expected to exceed 1,100 robots by month-end
Projected 2027 revenue of about $45.2 million under a five-year outlook that is not a guarantee of future performance
On October 20, 2026, iQSTEL issued senior secured, non-convertible promissory notes of up to $3 million in aggregate to M2B Funding Corp. and ADI Funding LLC, along with pre-funded warrants for 420,000 shares, to help fund its planned 51% acquisition of Ultranet Telecom Group. The notes carry 18% annual interest and are secured by a first-priority interest in company collateral, and the warrants could add dilution, so the financing adds debt cost and potential share issuance for shareholders while the acquisition itself is not yet signed.
Up to $3 million in notes, split between two purchasers: first $750,000 per purchaser funded on or about October 20, 2026, and a second advance of up to $750,000 per purchaser due on or before December 1, 2026
Notes bear 18% annual interest payable monthly in cash; principal repaid in four equal installments over 24 months
Warrants for 420,000 shares at a $0.0001 exercise price were fully issued at the initial closing; holders may accelerate at 120% of funded principal after an uncured default
Company expects to sign the Ultranet share purchase agreement in November 2026 and target closing in the middle of the first quarter of 2027
Faraday Future (FFAI) said its robotics business and related assets were transferred to FF EAI Robotics Ecosystem (Nasdaq: FFR) after an October 23, 2026 closing, with FFR issuing common and non-voting convertible preferred shares to Smart Technology Holdings, a FFAI subsidiary, as consideration. The filing gives FFR's standalone guidance of about 2,000 robots for 2026 and five-year projections, which the company says are not guarantees and do not represent FFR's consolidated 2026 results. For FFAI shareholders, the filing describes a shift from EV manufacturing toward robotaxi and robotics operations, but it does not report FFAI's own financial results or the value of its FFR stake.
Transaction closed October 23, 2026; FFR received the robotics business and related assets
FFR issued common and non-voting convertible preferred shares to Smart Technology Holdings Ltd., a FFAI subsidiary
FFR expects October 2026 sales and shipments above 300 robots and cumulative sales above 1,100 robots by end of October
FFR projects 2027 revenue of about $45.2 million and cumulative five-year revenue of about $1.98 billion
Commercial Bancgroup, Inc. reported third-quarter 2026 net income of $10.9 million, or $0.79 per diluted share, up from $9.5 million, or $0.77 per diluted share, a year earlier. Its board also declared a quarterly cash dividend of $0.12 per share, payable December 30, 2026, to holders of record on December 15, 2026.
Q3 2026 net income $10.9 million, or $0.79 per diluted share, versus $9.5 million, or $0.77, in Q3 2025
Nine-month net income $30.6 million, or $2.23 per diluted share, versus $27.1 million, or $2.22, a year earlier
Net interest margin 4.14% for the quarter, up 8 basis points from the second quarter of 2026
Quarterly cash dividend of $0.12 per share; record date December 15, 2026; payable December 30, 2026
The NYSE has begun proceedings to delist Eve Holding's public warrants, ticker EVEXW, and suspended trading in them because of an abnormally low selling price. The filing says the common stock, ticker EVEX, is not affected and continues to trade on the NYSE.
NYSE notified the company on October 21, 2026 and the company announced it publicly on October 22, 2026.
Warrants (EVEXW) are suspended from trading and the NYSE will apply to the SEC to delist them once procedures are complete.
Each warrant is exercisable for one share of common stock at $11.50 per share.
Common stock (EVEX) continues to trade on the NYSE, subject to the company's other listing requirements.
Luxfer Holdings PLC filed supplemental disclosures to its definitive proxy statement for its proposed $17.37-per-share cash sale to Double Eagle Acquisition Buyer, a Wynnchurch Capital-backed entity. The company said the disclosures respond to two New York lawsuits and demand letters alleging the proxy omitted material information, and that they do not change the consideration or the November 4, 2026 meeting timing. Shareholders are still asked to vote on the transaction, and the board continues to recommend voting FOR.
Proposed cash consideration is $17.37 per ordinary share; shareholder meetings are set for November 4, 2026.
Two lawsuits, Johnson v. Luxfer Holdings PLC and Thompson v. Luxfer Holdings PLC, were filed in the Supreme Court of the State of New York.
Supplemental disclosures cover standstill provisions, Deutsche Bank's discounted cash flow analysis (implied value $15.05 to $20.80 per share), and precedent transaction multiples.
The company says the allegations are without merit and that it denies all allegations in the actions.
Venu Holding Corp and subsidiaries executed agreements on October 20, 2026, selling the approximately 46-acre McKinney Parcel under The Sunset McKinney to STORE Capital Acquisitions, LLC and amending its Chapter 380 agreement with the City of McKinney. The city agreement lets the company keep operating control but adds a $3,000,000 cap on certain annual operations incentives and reduces a separated materials tax grant, while the company expects to be reimbursed the full $35,000,000 land purchase price if it meets construction milestones.
Land sale to STORE and the McKinney Sale-Leaseback closed on October 20, 2026, the Execution Date.
The company expects reimbursement of the full $35,000,000 land price ($10,000,000 cash plus $25,000,000 MEDC Note) if a TCO is received by December 3, 2027, or a CO by June 3, 2028.
Certain annual operations incentives for years 12 through 16 are capped at $3,000,000 in aggregate.
The filing excerpt does not state the sale-leaseback sale price.
On October 26, 2026, West Pharmaceutical Services entered a new credit agreement with Bank of America as administrative agent. It includes a $750 million revolving facility and a $200 million term loan advanced on the effective date, and the company used the borrowings to repay $130.0 million outstanding under its 2019 credit agreement, which it terminated with no early termination penalties. The filing reports no change to earnings or guidance, but it sets new debt terms, including a maximum net leverage ratio of 3.50 to 1.0.
New credit agreement provides a $750 million revolving facility and a $200 million term loan, with a five-year term from October 26, 2026.
$130.0 million outstanding under the 2019 credit agreement was repaid in full on October 26, 2026, with no early termination penalties.
Borrowings are unsecured; the net leverage covenant caps the ratio at 3.50 to 1.0, or 4.00 to 1.0 during material acquisition periods.
Term loan quarterly amortization starts March 31, 2028, at $1.25 million to $2.5 million per quarter, with the balance due at maturity.
Equillium said on October 26, 2026 that it dosed the first subject in its Phase 1 trial of EQ504 in Australia, which triggered the Milestone Closing of its August 2025 private placement. The company sold 14,957,260 shares at $0.57 and 20,130,457 pre-funded warrants at $0.5669 for gross proceeds of about $20.0 million before fees. The sale adds to the share count, and the company must file resale registration statements within 30 days, with cash penalties for registration failures.
Milestone Closing on October 26, 2026: 14,957,260 shares at $0.57 and 20,130,457 pre-funded warrants at $0.5669 each.
Gross proceeds of about $20.0 million before fees; total equity private placement proceeds of about $50 million.
Investors waived the $2.50 weighted average price threshold on October 26, 2026.
Registration statements for resale must be filed within 30 days of the Milestone Closing, with cash penalties for registration failures.
Onconetix, Inc. said its Board approved an additional one-for-ten reverse stock split of its common stock, which will bring the aggregate split ratio under the stockholder-approved authority to one-for-one hundred with a May 21, 2026 split. Shares are expected to begin trading on a split-adjusted basis on Nasdaq on November 6, 2026, under the existing symbol ONCO. The split reduces the share count but does not change any stockholder's percentage ownership, apart from cash paid for fractional shares.
Reverse split of one-for-ten is expected to take effect at 12:01 a.m. Eastern Time on November 6, 2026
Outstanding shares expected to fall from approximately 5.9 million to approximately 589,000
Combined with the May 21, 2026 split, the aggregate ratio is one-for-one hundred; new CUSIP 68237Q500 and symbol ONCO unchanged
No fractional shares will be issued; holders will receive cash in lieu, and authorized shares remain at 250,000,000
Noble reported a third-quarter 2026 net loss of $117 million, or $0.73 per diluted share, compared with a loss of $21 million a year earlier, and Adjusted EBITDA of $201 million versus $254 million. Full-year guidance narrowed, with the Adjusted EBITDA top end lowered to $900 million from $925 million and the Capital Expenditures range raised, which matters to shareholders because it signals lower top-end earnings and higher spending for 2026.
Q3 2026 total revenue was $729 million, versus $798 million in Q3 2025 and $720 million in Q2 2026.
Full-year 2026 Adjusted EBITDA guidance narrowed to $850-$900 million from $850-$925 million; revenue guidance narrowed to $2,850-$2,900 million.
Full-year 2026 Capital Expenditures guidance raised to $680-$705 million from $615-$665 million, primarily due to higher customer reimbursable spending.
Board approved a $0.50 per share dividend for Q4 2026, payable December 17, 2026, to holders of record on November 25, 2026.
Brown & Brown reported unaudited third-quarter 2026 results on October 26, 2026, with total revenues of $1.7 billion, up 7.4%, and net income attributable to the Company of $240 million, up 5.7%. Diluted net income per share fell 1.5% to $0.67, while adjusted diluted net income per share rose 1.9% to $1.07, and margins declined from the prior-year quarter.
Total revenues of $1.7 billion, up 7.4%; Organic Revenue growth of 1.2%
Net income attributable to the Company of $240 million, up 5.7%
Diluted net income per share of $0.67, down 1.5%; adjusted diluted net income per share of $1.07, up 1.9%
Income Before Income Taxes Margin of 18.6% vs. 19.4%; EBITDAC Margin - Adjusted of 34.6% vs. 36.6%
DataMEDS AI entered into a non-binding Second Amended and Restated Letter of Intent dated October 19, 2026, with EOS, Scilex, Datavault AI, HealthBridge Advisors and others to acquire QLPM intellectual property, expand a Datavault AI license, and take a controlling interest in Tollo Health, paid in company stock. The filing says existing public stockholders are expected to hold about 10.5% after closing, so the deal would substantially dilute current shareholders. Closing still requires definitive agreements, stockholder and Nasdaq approvals, and other conditions.
Target post-closing ownership: EOS 14.9%, Scilex 14.9%, Datavault 19.9%, Fortitude 5%, HBA and THI 24.9%, REBOOT 9.9%; existing public holders about 10.5%
Closing requires a liability threshold of not more than $2,000,000 and stockholder and Nasdaq approvals
Company agreed to reimburse Scilex, Datavault and EOS up to $250,000 in legal fees, payable at Closing
Exclusivity runs through November 30, 2026; Gerald Commissiong to serve as Interim Co-Chief Executive Officer
Eva Live said Streeterville Capital asserted that the company's October 2, 2026 Dune Equity Holdings deal breached the terms of two convertible notes, triggering a 10% increase in their outstanding balances. The company estimates the increase at about $741,786, raising the total to about $8,159,643, and disputes the lender's position and reserves all rights. Shareholders face potential added debt and possible legal or enforcement action, and the outcome is uncertain.
Streeterville's October 20, 2026 letter asserts a Major Trigger Event under each note as of October 2, 2026, and says the outstanding balances rose 10%.
The company estimates the balance would rise from about $7,417,857 to about $8,159,643, including about $522,302 on the February note and about $219,483 on the July note.
Streeterville has not delivered a cure demand or declared an Event of Default, according to the filing.
The company disputes the lender's assertions and says it is evaluating its options, which may include legal proceedings.
XBP Global Holdings disclosed that Chairman Par Chadha has told the company he will not seek re-election to the Board at the next annual meeting of stockholders. The company said the decision was not due to any disagreement over its operations, policies or practices, and Chadha will remain chairman and a director until his current term expires or he resigns earlier.
Par Chadha notified the company on October 20, 2026 that he will not stand for re-election as a director.
He will continue as Chairman and director until his current term expires, unless he resigns earlier.
The company stated the decision did not stem from any disagreement on operations, policies or practices.
Blue Ridge Bankshares reported a third-quarter 2026 net loss of $4.2 million, or ($0.05) per diluted share, wider than the $1.3 million loss in the second quarter and down from $5.6 million of net income a year earlier. Most of the credit provision tied to a single out-of-market loan relationship, while adjusted pre-tax earnings improved and the HomeTrust merger remains pending.
Net loss of $4.2 million, or ($0.05) per diluted share, versus net income of $5.6 million, or $0.06 per diluted share, in the third quarter of 2025.
Pre-tax provision for credit losses was $8.5 million, mainly linked to one out-of-market relationship; the company charged off $9.9 million on that borrower.
Adjusted pre-tax earnings rose to $5.3 million from $2.9 million in the second quarter of 2026.
HomeTrust merger agreement was announced August 17, 2026, and is expected to close in the first quarter of 2027, pending approvals.
Nasdaq granted Zeo Energy Corp. an additional 180 calendar days to regain compliance with the $1.00 minimum bid price rule for its Class A common stock. The company's stock listing and trading on the Nasdaq Capital Market are not immediately affected, but the company says there is no assurance it will regain compliance.
Nasdaq letter dated October 22, 2026 extends the compliance deadline to April 19, 2027.
The original 180-day compliance period was set to end October 20, 2026, after Nasdaq's April 23, 2026 notice.
The minimum closing bid price required is $1.00 per share for Class A common stock.
The company intends to monitor its bid price and consider options to regain compliance.
Nucor Corporation announced net earnings of $1.32 billion, or $5.80 per diluted share, for the third quarter of 2026, up from $1.16 billion in the second quarter. The company returned $629 million to stockholders through share repurchases and dividends during the quarter and expects fourth-quarter earnings to be generally in line with or modestly higher than the third quarter.
Net earnings attributable to Nucor stockholders were $1.32 billion, or $5.80 per diluted share, on net sales of $11.25 billion for Q3 2026.
The company returned approximately $629 million to stockholders in Q3 2026 through share repurchases and dividend payments.
Nucor repurchased approximately 2.03 million shares at an average price of $247.04 per share during the third quarter.
Rallybio's board declared an estimated $82.7 million special cash distribution, or about $13.56 per share, payable to holders of record as of November 5, 2026, in connection with its planned merger with Avenzo Therapeutics. Payment depends on stockholder approval at the November 4, 2026 annual meeting, and the actual amount may be higher or lower than the estimate. Shareholders buying during the due bill period (November 4 through November 6, 2026) will receive the distribution, while sellers will not.
Estimated cash distribution of $82.7 million, or $13.56 per share, based on 6,378,168 shares and equivalents outstanding as of October 21, 2026
Record Date November 5, 2026; ex-dividend date expected November 6, 2026; distribution scheduled for November 13, 2026
Payment conditioned on Required Company Stockholder Vote at the annual meeting at 10:00 a.m. Eastern Time on November 4, 2026
Merger closing expected on or about November 6, 2026
On October 20, 2026, Soren Acquisition Corp. replaced its chief financial officer and changed three of its board seats, with Joseph Tonnos becoming CFO in place of Jamie Weber, who also resigned as a director. Arghavan Di Rezze remains chief executive officer. The filing reports no financial results, and the compensation for the new directors and CFO has not been determined.
Joseph Tonnos was appointed CFO effective October 20, 2026, succeeding Jamie Weber, who resigned as CFO and director.
Spencer Gerrol and Charles N. Kahn III resigned as directors effective October 20, 2026; Roger Cloutier Jr., Austin Criden and Joseph Tonnos filled the three vacancies.
Compensation for the new directors and CFO has not been determined; each is expected to receive an indirect economic interest in founder shares held by sponsor Soren Holdings LLC.
The company furnished an October 26, 2026 press release announcing the appointments as Exhibit 99.1.
Mirum Pharmaceuticals said its 25-patient Cohort 2 trial of ATEBRIOZ (zilurgisertib) in children aged 6 to under 12 with fibrodysplasia ossificans progressiva showed reduced heterotopic ossification lesion volume and improved joint mobility at Week 24 compared with placebo. The company plans to submit a supplemental New Drug Application in the first half of 2027 to expand the approved indication to this age group.
Mean total HO lesion volume fell 8.09 cm³ with ATEBRIOZ versus a 9.14 cm³ increase with placebo (nominal p=0.003).
No ATEBRIOZ-treated patients developed new HO lesions, compared with 1 patient (7.7%) on placebo.
Mean CAJIS joint mobility score improved 0.80 points with ATEBRIOZ versus 0.09 points with placebo at Week 24.
The company plans a supplemental NDA submission in the first half of 2027; full Cohort 2 results will be presented at an upcoming medical meeting.
Longeveron reported updated ELPIS II Phase 2b results for laromestrocel in 40 infants with hypoplastic left heart syndrome. The trial did not meet its primary endpoint of change in right ventricular ejection fraction at Month 12, but a pre-specified secondary endpoint, major adverse cardiac events (MACE), reached statistical significance. The company plans to request an FDA meeting, and the results are scheduled for presentation at the AHA 2026 Scientific Sessions.
Primary endpoint not met: mean RVEF decreased 2.6 percentage points in the standard of care group and 3.3 points in the laromestrocel group, with no statistically significant difference (p=0.68).
MACE: 8 events in the standard of care arm versus 1 in the laromestrocel arm (P=0.043).
FDA previously advised Longeveron that RVEF alone would not be sufficient to demonstrate efficacy for regulatory approval.
Data selected for a late-breaking podium presentation at AHA 2026 Scientific Sessions on November 8, 2026, in Chicago.
Flexsteel reported fiscal first-quarter 2027 results for the period ended September 30, 2026, with net sales up 3.2% to $114.0 million. Operating income fell to $6.9 million from $9.0 million, and diluted earnings per share dropped to $1.24 from $1.31, as gross margin declined on currency effects and higher energy and material costs. The company expects second-quarter sales of $119.5 million to $123.0 million and a GAAP operating margin of 6.5% to 7.0%.
Net sales were $114.0 million, up 3.2% from $110.4 million; Flexsteel-branded sales rose 5.1% while the exited Homestyles line fell 57.6%.
GAAP operating income was $6.9 million, or 6.0% of net sales, versus $9.0 million, or 8.1%, a year earlier.
Diluted EPS was $1.24 versus $1.31; net income was $5.4 million versus $7.3 million.
For the quarter ending December 2026, the company guides to sales of $119.5 million to $123.0 million (1% to 4% growth) and a 6.5% to 7.0% operating margin; a conference call is set for October 27, 2026 at 8:00 a.m. Central Time.
Cumberland Pharmaceuticals plans to submit a New Drug Application to the FDA for ifetroban as a treatment for cardiomyopathy associated with Duchenne muscular dystrophy, seeking Traditional Approval based on its FIGHT DMD trial and natural history data. The FDA raised concerns that the proposed data package may not be sufficient to show substantial evidence of efficacy and requested additional analysis, and the company states there is no assurance the FDA will accept the filing or approve the drug.
The 12-month Phase 2 FIGHT DMD trial showed a statistically significant 5.4% absolute improvement in left ventricular ejection fraction (p=0.002) versus a control group.
The FDA suggested a Phase 3, randomized, placebo-controlled trial earlier in the review process, and expressed concerns about the sufficiency of the proposed data package at a pre-NDA meeting held this fall.
The FDA granted the company's request for rolling review of the NDA, allowing completed sections to be submitted before the full application.
The planned submission includes safety data from more than 1,400 subjects across approximately 30 clinical studies of ifetroban.
Praetorian Acquisition Corp. announced a leadership transition effective October 20, 2026. Peter Ondishin resigned as Chief Financial Officer and director, and Joseph Tonnos was appointed CFO, while three directors resigned and three new independent directors were appointed. Justin Di Rezze, M.D. continues as Chief Executive Officer, and the compensation arrangements for the new directors and CFO have not been determined.
Nicole Seligman, Erica Dorfman and Alex Elias resigned as directors effective October 20, 2026; they also served on the Audit and Compensation Committees.
Peter Ondishin resigned as Chief Financial Officer and director effective October 20, 2026.
Joseph Tonnos was appointed Chief Financial Officer and a Class II director; Roger L. Cloutier Jr., Jimmy Vaiopoulos and Charles P. Garcia were appointed as directors.
Compensation for the new directors and CFO has not been determined; they will enter the Company's standard director indemnity agreement.
On October 26, 2026, Francisco Partners completed its acquisition of Weave Communications, and Weave stock stopped trading on the New York Stock Exchange. Stockholders received $7.40 in cash per share, and the company repaid its existing credit facility and entered a new credit agreement with Hercules Capital. Shareholders no longer hold Weave stock, and the company will operate as a privately held company.
Stockholders receive $7.40 per share in cash, a premium of about 34% to the unaffected closing price on August 17, 2026.
Total merger consideration was about $597.46 million; the transaction was valued at about $650 million.
Weave common stock ceased trading and is no longer listed on the NYSE.
New Credit Agreement with Hercules Capital provides a $190 million initial term loan, a $25 million delayed draw term loan and a $25 million revolving credit facility.
TrueBlue appointed Elizabeth Castro Gulacsy, former CFO of United Parks & Resorts, as an independent director effective October 26, 2026, and she joins the Audit Committee. The appointment was made under a Cooperation Agreement with Eric H. Su and related entities dated April 10, 2026, and it expands the board to ten directors.
Elizabeth Castro Gulacsy appointed to the board effective October 26, 2026; board increased from nine to ten directors
She will serve on the Audit Committee; nine of the ten directors are independent
Appointment made under a Cooperation Agreement with Eric H. Su, EHS Management LLC and EHS Azure Opportunity Fund LP dated April 10, 2026
Prior roles include CFO and Treasurer of United Parks & Resorts and Chief Accounting Officer at Cross Country Healthcare
FirstSun Capital Bancorp reported third-quarter 2026 net income of $38.4 million, or $0.82 per diluted share, compared with a net loss of $22.9 million in the second quarter. Adjusted net income, a non-GAAP measure, was $48.2 million, or $1.03 per diluted share. Results were driven by lower noninterest expense after merger-related costs fell, and a higher net interest margin.
Net income $38.4 million, $0.82 per diluted share, versus a net loss of $22.9 million, or $0.49 per share, in Q2 2026; Q3 2025 diluted EPS was also $0.82
Adjusted net income $48.2 million, $1.03 per diluted share, versus $21.0 million, $0.45 per share, in Q2 2026
Net interest margin rose 24 basis points to 3.82%; noninterest expense fell $45.2 million to $126.6 million, with merger-related expenses down $44.3 million
Repurchased 1,245,224 common shares for $49.7 million; core system conversion of First Foundation completed in late September 2026
Applied Materials entered into an accelerated share purchase agreement on October 26, 2026, to buy more shares of BE Semiconductor Industries (Besi). Including its existing holding, Applied would own about 20% of Besi's outstanding shares. Delivery of the shares depends on the expiration or termination of the HSR Act waiting period, and the filing gives no purchase price or financial impact.
Post-purchase ownership would be about 20% of Besi's outstanding common stock, including Applied's existing shares.
Applied first invested in Besi in April 2025 and says the stake is long term.
Share delivery is subject to the expiration or termination of the HSR Act waiting period.
Applied says it has no current intention to go above 20% and does not intend to seek a Besi board seat.
Health In Tech appointed Sanjay Shrestha as Chief Executive Officer effective October 20, 2026, succeeding founder Tim Johnson, who became Executive Chairman on the same date. The filing sets out Shrestha's employment terms and restricted stock awards, and part of the equity grant depends on stockholder approval of a plan amendment.
Shrestha, age 52, previously served as a director from April 2025 until his resignation in August 2026.
Base salary is $500,000, increasing to at least $700,000 upon the Company raising at least $10,000,000.
Sign-On Award of 2,000,000 Class A shares; Market Capitalization Awards total 4,500,000 shares.
MC-2, MC-3 and MC-4 tranches (2,500,000 shares) depend on stockholder approval at the November 10, 2026 annual meeting.
Welltower Inc. reported third quarter 2026 net income of $415 million and raised its full-year guidance for net income and normalized FFO per diluted share. The company also declared a quarterly cash dividend of $0.85 per share.
Reported net income of $415 million and normalized FFO of $1.67 per diluted share for Q3 2026.
Raised full-year 2026 net income guidance to a range of $3.31 to $3.37 per diluted share.
Declared a quarterly cash dividend of $0.85 per share, payable on November 19, 2026.
Closed or under contract to close $21.0 billion of pro rata gross investments year-to-date.
Dorman Products reported third-quarter 2026 net sales of $561.7 million, up 3.3%, but diluted EPS fell 20% to $1.98 and adjusted diluted EPS fell 21% to $2.08. The company narrowed its full-year 2026 guidance, lowering the top end of its net sales growth range to 2% to 3% from 3% to 5%, which matters to shareholders because sales growth is slowing while profit is down from the prior year.
Net sales of $561.7 million, up 3.3% from $543.7 million; gross margin fell to 39.4% from 44.4%.
Diluted EPS of $1.98 vs. $2.48 a year earlier; adjusted diluted EPS of $2.08 vs. $2.62.
Full-year 2026 net sales growth guidance narrowed to 2% to 3% from 3% to 5%; adjusted diluted EPS guidance is $8.50 to $8.70, down from $8.50 to $8.80.
Repurchased $15 million of shares in the quarter; year-to-date repurchases total $112 million, a company record.
Northpointe Bancshares' Board approved a stock repurchase program of up to $30 million of its outstanding common stock, running from October 22, 2026 to October 22, 2027. The filing says repurchases may be made in the open market or in privately negotiated transactions, and the program can be changed or ended at any time, so shareholders would see the effect only as shares are actually bought.
Program authorizes up to $30 million of outstanding common stock repurchases
Program period runs from October 22, 2026 through October 22, 2027
Repurchases may occur in the open market or in privately negotiated deals, and may use Rule 10b5-1 plans
Chairman and CEO Chuck Williams cited confidence in the business model and strong capital position
Seres Therapeutics said Chief Financial Officer Marella Thorell resigned from her executive vice president and CFO roles on October 22, 2026, effective November 15, 2026. The company said she is expected to provide advisory services after that date to support an orderly transition, on terms still to be agreed.
Marella Thorell resigned as EVP and Chief Financial Officer on October 22, 2026
Resignation takes effect November 15, 2026
Thorell is expected to provide advisory services to support an orderly transition, terms not yet agreed
OpenWorld preliminarily estimated third-quarter 2026 revenue of $6.9 million to $7.2 million and a GAAP net loss of about $10.0 million, which includes about $11.9 million of nonrecurring stock-based compensation and merger-related fees. The company also named Gerard Hernandez Chief Financial Officer effective October 23, 2026, after removing Jennifer Cola from the role. The estimates are unaudited and not yet reviewed by the auditor, and the company will report final results on November 12, 2026.
Estimated Q3 2026 revenue of $6.9 million to $7.2 million, with gross margin of 80% to 82%
Estimated GAAP net loss of about $10.0 million, including about $11.9 million of nonrecurring stock-based compensation and merger-related fees
Estimated adjusted EBITDA (non-GAAP) of $1.7 million to $2.0 million
Gerard Hernandez named CFO effective October 23, 2026; Jennifer Cola was removed as CFO effective the same date
Unitil's subsidiary Maine Natural Gas issued $40 million of 5.95% senior unsecured notes due October 21, 2031, and the parent repaid all outstanding amounts under its Bank of Nova Scotia credit agreement on October 22, 2026. The notes are intended to refinance existing company debt and for general corporate purposes, and the repayment of the credit facility is a financing refinancing step with no reported change in earnings or guidance.
Maine Natural Gas Corporation sold $40,000,000 of 5.95% Senior Unsecured Notes due October 21, 2031, under a Note Purchase Agreement dated October 21, 2026.
Unitil repaid all outstanding amounts under its Amended and Restated Credit Agreement with The Bank of Nova Scotia on October 22, 2026, without premium or penalty.
The credit agreement had a borrowing limit of $86.0 million for tranche A and $50.0 million for tranche B, and the company may not reborrow repaid amounts.
Net proceeds are planned for refinancing existing debt of the company and/or general corporate purposes.
H2O America reported third quarter 2026 GAAP diluted EPS of $0.99, down from $1.27 a year earlier, while operating revenue rose 4% to $250.2 million on rate increases. The company narrowed its standalone 2026 adjusted EPS guidance to $3.10-$3.16 and set a separate 2026 guidance range of $2.91-$2.97 that includes the Quadvest and pending Cibolo Valley acquisitions, so shareholders face higher share count and acquisition-related dilution in the near term.
Q3 2026 GAAP net income was $43.0 million, down 5%; adjusted diluted EPS was $1.04 versus $1.27 a year earlier
Standalone 2026 adjusted EPS guidance narrowed to $3.10-$3.16, midpoint unchanged at $3.13; guidance including acquisitions is $2.91-$2.97
Quadvest acquisition closed October 1, 2026 for $542.7 million in cash; Cibolo Valley closing expected November 2, 2026
Quarterly dividend of $0.44 per share declared, payable December 1, 2026
German American Bancorp reported record net income of $38.6 million, or $1.03 per share, for the quarter ended September 30, 2026, up from $1.02 per share in the prior quarter and $0.94 per share a year earlier. The Board also declared a $0.31 per share cash dividend, payable November 20, 2026, to shareholders of record as of November 10, 2026.
Net income of $38.6 million, or $1.03 per share, versus $38.2 million, or $1.02 per share, in the second quarter of 2026
Net interest margin rose to 4.42% from 4.30% in the second quarter of 2026
Non-interest expense increased to $53.1 million, up $2.7 million from the second quarter of 2026
Cash dividend of $0.31 per share payable November 20, 2026 to holders of record on November 10, 2026
C&F Financial Corporation reported third-quarter 2026 net income of $8.3 million, up 16.1% from $7.1 million a year earlier, and nine-month net income of $23.7 million, up 16.8%. Nine-month results include a $8.3 million pre-tax gain on the sale of an equity interest in Bearing Insurance Group and a $7.1 million pre-tax loss from a securities portfolio restructuring, and adjusted nine-month net income rose 13.1% to $22.9 million.
Q3 2026 earnings per share were $2.55, up from $2.18 in Q3 2025, but down from $2.63 in Q2 2026.
Nine-month 2026 earnings per share were $7.26, up from $6.22 a year earlier; adjusted earnings per share were $7.03.
Community banking loans grew $148.1 million, or 9.6%, from September 30, 2025, and the consolidated net interest margin was 4.53% in Q3 2026 versus 4.24% a year earlier.
The Board-approved 2026 share repurchase program allows up to $5.0 million of repurchases; the company repurchased 3 shares, or less than $1,000, in Q3 2026.
Celestica reported third-quarter 2026 revenue of $5.83 billion, up 83% from a year earlier, and adjusted EPS of $3.30, above its $2.88 to $3.08 guidance range. It raised its 2026 revenue outlook to $21.0 billion and adjusted EPS outlook to $11.55, and gave a first 2027 outlook of $40.0 billion in revenue and $21.50 adjusted EPS, which matters to shareholders because it signals higher expected earnings. The company cut its 2026 free cash flow outlook to $460 million from $600 million, citing working capital investments.
Q3 2026 adjusted EPS was $3.30 and GAAP EPS was $3.26, compared with $1.58 and $2.31 in Q3 2025.
2026 outlook raised: revenue of $21.0 billion (previously $20.5 billion) and adjusted EPS of $11.55 (previously $11.30).
2026 free cash flow outlook lowered to $460 million from $600 million, primarily due to working capital investments to support 2027 growth.
2027 outlook: revenue of $40.0 billion and adjusted EPS of $21.50; a new normal course issuer bid is planned for Q4 2026 after the current one expires November 2, 2026.
Nasdaq elected Börje Ekholm, former President and CEO of Ericsson, to its Board of Directors effective November 1, 2026, where he will serve on the Audit & Risk Committee. Director Holden Spaht will leave the Board and all committees effective December 31, 2026, and the company said his decision was not due to any disagreement with Nasdaq. The changes are board composition updates that do not alter reported financial results.
Börje Ekholm elected to the Board on October 21, 2026, effective November 1, 2026, and named to the Audit & Risk Committee
Ekholm was President and CEO of Ericsson from January 2017 to September 2026 and previously chaired Nasdaq's Board from May 2012 to December 2016
Holden Spaht notified Nasdaq on October 22, 2026 of his resignation from the Board, effective December 31, 2026
A non-officer immediate family member of Ekholm is employed by Nasdaq; the Audit & Risk Committee reviewed and ratified that compensation
Piedmont Realty Trust reported a third quarter 2026 net loss of $21.0 million, or $0.17 per diluted share, compared with $13.5 million, or $0.11 per share, a year earlier. The loss included a $20.2 million loss on early extinguishment of debt, while third quarter Core FFO rose to $0.39 per diluted share from $0.35, and the company raised its 2026 Core FFO outlook to $1.55-$1.57 per diluted share from $1.47-$1.53.
Net loss of $21.0 million ($0.17 per diluted share) for Q3 2026, vs. a $13.5 million loss ($0.11) in Q3 2025
Total revenues of $151.2 million for Q3 2026, vs. $139.2 million in Q3 2025
Core FFO of $0.39 per diluted share for Q3 2026, vs. $0.35 a year earlier; 2026 Core FFO outlook raised to $1.55-$1.57 from $1.47-$1.53
Cash rent roll up of 26.2% on Q3 2026 leasing; in-service portfolio 87.7% leased as of September 30, 2026, down from 88.9% on June 30, 2026
Phillips Edison & Company reported third quarter 2026 net income attributable to stockholders of $62.7 million, or $0.49 per diluted share, up from $24.7 million, or $0.20, a year earlier. Core FFO rose 11.3% to $100.7 million, or $0.71 per diluted share, and the company raised the low end of its full-year 2026 Core FFO guidance to $2.75 to $2.79 per diluted share.
Q3 2026 Core FFO of $0.71 per diluted share, up 9.2% year over year on a per-share basis; Nareit FFO of $0.69 per diluted share
Full-year 2026 net income per diluted share guidance raised to $1.21 to $1.24, from $0.95 to $0.97
Full-year 2026 Core FFO guidance is $2.75 to $2.79 per diluted share, up from $2.73 to $2.79; same-center NOI growth guidance is 3.50% to 4.00%
Subsequent to quarter end, the company closed a new $350 million unsecured term loan maturing October 23, 2029
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.